• ChemoMetec fiscal 2025/26 revenue rose 3% to DKK 511.1 million; EBITDA climbed to DKK 281.3 million from DKK 258 million.
• EBITDA margin widened 3 percentage points to 55%; net profit increased to DKK 201.8 million from DKK 174.7 million.
• Instrument revenue jumped 13% while service rose 4%; consumables fell 4%.
• XcytoMatic instrument sales more than doubled to DKK 61.8 million from DKK 27.7 million, helped by the phase-out of older instruments.
• Guides 2026/27 revenue of DKK 545-575 million; targets EBITDA of DKK 300-315 million, focusing on XcytoMatic marketing and partner-led automation solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ChemoMetec A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609101439OMX_____CNEWS_DA_GNW1001262146_da) on September 10, 2026, and is solely responsible for the information contained therein.